Despite the efficacy of current treatments, viral persistence remains a significant hurdle in the fight against Hepatitis B. The ability of the virus to integrate its genetic material into the host's genome allows it to remain dormant and evade the immune system for decades. Addressing this persistence requires a combination of potent antivirals and new therapeutic vaccines that can stimulate a durable T-cell response. The industry's goal is to transition the infection from a life-threatening chronic condition to a manageable—and eventually eradicable—disease.

According to analysis of the Hepatitis B Treatment Market, the focus on "Functional Cure" endpoints is the primary catalyst for new investment. Public-private partnerships are accelerating the development of therapies that can safely clear HBsAg from the blood, a milestone that significantly reduces the risk of liver cancer. As these advanced therapies reach the market, they are expected to displace older, less effective treatments, reshaping the competitive landscape and setting a new benchmark for what is possible in the field of viral hepatology.